BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 2, 2014
View Archived Issues
ADN-3662 demonstrates activity in well-recognized in vivo models of mood deficits
Read More
New mTOR inhibitors discovered at Sanofi
Read More
Preclinical profile of basimglurant described
Read More
Atox Bio awarded BARDA contract for development of AB-103
Read More
Phase IIa topline results for dupilumab in patients with chronic sinusitis with nasal polyps
Read More
Tonix reports topline data from BESTFIT study of TNX-102 SL for fibromyalgia
Read More
Helix BioPharma reports interim data from phase I/II trial of L-DOS-47
Read More
Sarepta Therapeutics reports favorable data from phase I trial of antisense therapy for influenza
Read More
Lumara Health to be acquired by Amag Pharmaceuticals, sells women's health assets to Perrigo
Read More
Dimerix Bioscience receives approval to begin phase II trial of DMX-200
Read More
Phase II data presented in patients with CMV and adenovirus resistance profiles
Read More
Model of autoimmune optic neuritis used to assess new treatment strategy
Read More
Novel candidates for neuropathic pain prepared at Nippon Chemiphar
Read More
Novel fusion proteins patented by Pfizer as N. meningitidis vaccines
Read More
Merck KGaA divulges novel GCN2 inhibitors
Read More
Gedeon Richter presents new histamine H3 receptor antagonists
Read More
New LRRK2 inhibitors disclosed by Merck & Co.
Read More
Epigen Biosciences discloses novel LPA-1 receptors
Read More
Reata cleared to run phase II studies of RTA-408 in Friedreich's ataxia and mitochondrial myopathies
Read More
Kamada confirms second extension of strategic agreement with Baxter
Read More
Compugen reports new results for CGEN-15049 target candidate
Read More
Portola reports successful outcome from first phase III study of andexanet alfa
Read More
Enanta regains full rights from Novartis to EDP-239 for HCV
Read More
Zafgen begins phase III trial of beloranib in Prader-Willi syndrome
Read More
OnCore Biopharma to acquire Enantigen Therapeutics
Read More
Alnylam initiates observational EXPLORE study in hepatic porphyrias
Read More